In a significant medical feat, Indian scientists have developed the first-in-human gene therapy using lentiviral vectors for ...

Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, venous access ...

Haemophilia is a severe bleeding disorder caused by the deficiency of clotting Factor VIII, leading to spontaneous internal ...

The popularity of viral vector-based gene therapies and vaccines is rapidly growing. However, it is often difficult for scientists to ramp up the generation of these vectors to meet their needs at ...

India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

Vyriad’s lentivirus vectors target T cells within a patient’s body and deliver genes coding for chimeric antigen receptors. Once the T cells decipher those genetic instructions, they are ...

Breakthrough in Delivering Chimeric Bait Receptors to Immune Cells Accelerates Development LONDON, UK / ACCESSWIRE / December ...

They can infect both dividing and non-dividing cells and provide stable, long-term gene expression. Lentiviral vectors, derived from HIV-1, are widely used in research and clinical applications.

The FDA notification came seven weeks after the New England Journal of Medicine (NEJM) published a report that seven of 67 ...